News Hub | News Direct

All Industries


Article thumbnail News Release

Tokenization Gains Momentum With Collaborative Effort By Financial Giants And The European Central Bank – Diamond Lake Minerals (OTCPK: DLMI) Stays Ahead Of The Curve

Benzinga

By Gerelyn Terzo, Benzinga The tokenization of financial assets has been a game changer for investors and business owners alike. This technological innovation has paved the way for both individual investors and entrepreneurs to go further than they could before the advent of blockchain. Tokenization includes a type of fractional ownership in which investors hold a piece of an asset rather than needing to be able to afford the entire cost of a high-priced asset, like a piece of land. As a result, investors share the costs and rewards with other members. Additionally, tokenization represents a tool for businesses to enter the digital age and create new opportunities for stakeholders. In this growing space, companies like Diamond Lake Minerals (OTCPK: DLMI) are at the forefront of innovation and the digital revolution. Tokenization Overview While tokenization and cryptocurrencies like Bitcoin are often associated, they’re not synonymous. Bitcoin, the maiden cryptocurrency, is a decentralized digital asset that can be exchanged for payments on a peer-to-peer network without the need for a third party like a bank. Bitcoin is the digital currency underpinning the blockchain that bears its name. While tokenized assets similarly transact on the blockchain, they serve a different purpose than Bitcoin. They’re representations of physical assets – including anything from real estate to gold to fiat money like the dollar or euro – that are converted into digital form. Tokenized assets are disrupting financial services across securities settlements, investments and payments. As big as Bitcoin is, with a market cap of $1.3 trillion, tokenization has the potential to be 100 times bigger, according to Larry Fink, CEO of the world’s biggest asset manager, BlackRock. Banks Embrace Tokenized Assets While major financial institutions were slow to warm up to the idea of digital assets and the blockchain, they’re starting to come around. They’re drawn to the features of a decentralized ledger, including cost efficiency, speedy transaction settlement times and security, thanks to the immutable nature of the blockchain. In hindsight, it was only a matter of time before they came on board. In addition to Wall Street banks, central banks have taken notice, too. Most recently, a trio of major firms, JPMorgan (NYSE: JPM), Deutsche Bank (NYSE: DB) and BNP Paribas, have partnered with the European Central Bank (ECB) to test the mettle of blockchain technology for settling security transactions in the financial markets. This groundbreaking experiment not only has the potential to disrupt securities settlement when assets like stocks and bonds are traded, but it could also help bring clarity to the role of digital assets in the global financial system. The bank project remains in the early stages and is expected to unfold through Q4 2024. In the meantime, it sends a message to other banks and central banks that it won’t be long before blockchain technology is more fully integrated into the financial markets. Payments aren’t too far behind, either. Mastercard (NYSE: MA) has been making strides in tokenizing fiat payments on the blockchain. The card giant, along with partner Standard Chartered in Hong Kong, completed an experiment for tokenized bank deposits on the blockchain using the Mastercard Multitoken Network (MTN), which comprises a set of tools designed to support this process. As part of the test program, Standard Chartered’s digital arm, Mox Bank, purchased a carbon credit, in turn requesting its tokenization by yet another subsidiary, Libeara. The tokenization of the carbon credit was fulfilled through MTN via an atomic swap between the two instruments, the carbon credit and digital asset. The deposit, which was overseen by the Hong Kong Fintech Supervisory Sandbox, was successfully completed. It is a step toward “the tokenization of real-world assets,” according to Standard Chartered CEO Mary Huen, ranging from carbon credits to the transfer of loans. The involvement of the Hong Kong regulator demonstrates both the need for oversight in the tokenization of the monetary system and the role that gatekeepers will play. Diamond Lake Minerals Pioneers Tokenization While banks and card networks might only now be dipping their toes into the tokenized waters, companies like Diamond Lake Minerals (OTCMKTS: DLMI) are already making strides. Diamond Lake Minerals has been extremely focused on tokenization since August of 2023, when Brian J. Esposito took over as CEO and transformed the company’s vision and strategy. Esposito has been pioneering this approach over the last decade, bridging traditional finance and digital assets. In Salt Lake City, Utah, Diamond Lake Minerals, led by Esposito, is heavily involved in the regulated digital asset space, bringing opportunities like registered security token offerings to investors. DLMI stock is one way for investors to potentially gain exposure to the blockchain without having to go too far down the rabbit hole on digital wallets and security. Importantly, the blockchain space remains a nascent playground in which the rules are still being written. Diamond Lake prioritizes the regulatory guardrails that exist, erring on the side of caution so there’s no gray area. “We look at everything as a security because we want it to have value. We want it to be backed by real assets and we want it to create a return,” said Esposito in a recent podcast. Most recently, Diamond Lake Minerals has teamed up with modular home developer BOXABL in an alliance through which entire communities – BOXABL Villages, as they’re called – are being developed and financed. They’re using a combination of security tokens and traditional means, a technology-fueled balance of liquidity that the company believes is especially valuable in the current high-interest rate environment. This confluence of modular homes and digitalization accelerates the homebuying process while providing much-needed affordable housing supply to the market. Investors who are looking to add diversification to their portfolios or business owners interested in pursuing tokenization for their real-world assets may want to look at Diamond Lake Minerals to see if it matches their goals and risk-reward profile. Featured photo by HoAnneLo on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 22, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Benzinga

By Kyle Anthony, Benzinga MAIA Biotechnology (AMEX: MAIA) is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. The company’s mission is to discover, develop and deliver transformative cancer therapies that improve patients' lives worldwide. MAIA Biotechnology envisions a future where cancer is manageable and patients can live longer, healthier lives. The firm is at the forefront of revolutionizing oncology, leveraging advanced scientific research and technological advancements to drive its progress, with the goal of bringing treatments that target cancer's replication mechanism in a more efficacious and less harmful manner than traditional therapies. Company Background Founded in August 2018 and headquartered in Chicago, Illinois, MAIA Biotechnology is led by an experienced management team and supported by scientific advisors with extensive drug development experience who are committed to advancing promising agents into human clinical trials. MAIA Biotechnology specializes in telomere-targeting therapies for cancer treatment. As such, the firm’s current product focus is the development of first-in-class drugs that target proteins that control how cancer cells grow, divide and spread. MAIA Biotechnology's pipeline includes several promising candidates in various stages of development, but its premier product offering is THIO (6-thio-2′-deoxyguanosine), a first-in-class telomere-targeting agent designed to selectively kill telomerase-positive cancer cells, which are present in most human cancers. The Role Of Telomeres In Cancer Telomeres play a crucial role in cellular aging and cancer development. Research published by the Dana-Farber Cancer Institute explains that cancer cells often avoid senescence or cell death by rebuilding and maintaining their telomeres despite repeated cell divisions. This is possible because the cancer cells activate an enzyme called telomerase, which adds genetic units to the telomeres to prevent them from shortening to the point of causing cell death. As a result, cancer cells essentially become immortal. Telomerase is silenced in most normal cells but is active in an estimated 85% to 95% of human cancer cells. Since telomerase is active in cancer cells but not normal cells, it is seen as a promising target for cancer therapy. Due to telomerase inhibition, activity or expression, telomere-targeting drugs might kill tumor cells by allowing telomeres to shrink or by provoking apoptosis, the process of programmed cell death. By incorporating into telomeres, THIO disrupts their function, leading to cancer cell death. This approach has shown promising preclinical results and has been undergoing clinical trials. Product Development Pipeline THIO is MAIA Biotechnology’s most advanced product offering, which has shown positive efficacy findings in treating advanced non-small cell lung cancer (NSCLC) in clinical trials. The ongoing clinical trial is testing the hypothesis that lower doses of THIO administered before immune checkpoint inhibitor Libtayo® treatment (i.e., stimulation of the immune system to attack cancer cells) would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progress after first-line treatment with a checkpoint inhibitor, a type of drug that blocks proteins called checkpoints that are made by some types of immune system cells such as T cells and some cancer cells. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. The clinical trial's positive results support THIO's tolerability and safety as an anticancer therapy and a priming immune activator. Treatment with THIO sequenced with Libtayo® treatment was found to be well-tolerated in a heavily pre-treated population thus far. MAIA Biotechnology is also researching other drug treatments, using its expertise in telomere-targeting agents as a foundation. The company’s second-generation program aims to discover new compounds with potentially improved specificity toward cancer cells relative to normal cells and potentially increased anticancer activity. This program will allow MAIA Biotechnology to strengthen its patent portfolio over time, which already has five issued patents and 29 applications pending worldwide. Market Potential and Industry Impact Research published by Coherent Market Insights estimates the cancer therapy market will be worth $205.10 billion in 2024 and is expected to reach $466.21 billion by 2031. The driving factors behind this growth are the rising occurrence of cancer worldwide and the increasing demand for cancer treatment. As such, MAIA Biotechnology‘s THIO addresses a large and growing market. As outlined in their most recent corporate presentation, lung and colon cancer are the first and second most prevalent cancer types globally, respectively, and treating them specifically would generate billions in sales. Given the current opportunity, MAIA Biotechnology will continue to protect its intellectual property while expanding its patent portfolio. Recently, the Food and Drug Administration (FDA) granted a third orphan drug designation (ODD) to THIO as a treatment for glioblastoma; the drug also holds ODDs for hepatocellular carcinoma and small-cell lung cancer. The glioblastoma market is expected to grow from $2.2 billion to $3.2 billion globally in the next three years. The FDA’s ODD program provides multiple incentives to make orphan drug development more financially feasible for companies. These include up to seven years of market exclusivity for the approved orphan drug, up to 20 years of 25% federal tax credit for expenses incurred in conducting clinical research within the U.S., and waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, a value of approximately $2.9 million in 2021. Conclusion MAIA Biotechnology’s approach to cancer treatment differentiates it from its peers, potentially placing the company in a unique market position. As incidences of cancer continue to rise globally, drug treatment options, such as THIO, will likely rise in demand. As such, the benefit that MAIA Biotechnology provides and the value proposition the firm espouses will likely continue to have industry resonance. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 22, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

JustiFi Raises New Capital to Help Platforms Reach Their Fintech Potential

Rally Ventures

JustiFi, the fintech platform for platforms, today announced it raised $10 Million in a funding round co-led by existing investors Rally Ventures, Emergence Capital and Crosslink Capital and a debt facility from Silicon Valley Bank. This infusion of capital underscores JustiFi's dedication to enhancing the fintech capabilities of its expanding roster of platform customers. By seamlessly integrating payments, insurance, and Buy Now, Pay Later (BNPL) solutions into a single, user-friendly Unified Fintech Checkout, JustiFi empowers its clients to streamline their operations and unlock their full fintech potential. With the Unified Fintech Checkout (UFC), platform companies gain access to a comprehensive suite of white-label fintech products ready for deployment to their existing customer base. This empowers platforms to tap into new revenue streams while offering essential fintech solutions to both their customers and the businesses they serve. The UFC's implementation is seamless, utilizing a web component that enables platforms to launch embedded payments, insurance, and BNPL in a single sprint, significantly reducing deployment time from months or even years to just a few weeks. According to a recent Goldman Sachs report, achieving transformative fintech results hinges not only on cutting-edge technology but also on widespread adoption. While an embedded fintech infrastructure lays a solid foundation, for platforms, true success and customer satisfaction stem from comprehensive fintech integration. Recognizing this, JustiFi's Engage™ fintech team works closely with its platform customers to drive fintech activation from onboarding and beyond. Offering a range of services including fintech goal setting, UI and UX design, technical implementation, and go-to-market strategy, JustiFi aims for nothing short of 100% payments adoption for each and every one of their customers. "This new investment underlines the confidence of our investors in JustiFi and our belief that vertical platforms should not only facilitate seamless financial transactions for their customers but also retain the majority of the benefits derived from them," said JustiFi Co-Founder and CEO Joe Keeley. "In a world where fintech integration is a strategic imperative for platforms, JustiFi makes it easy to seamlessly integrate payments and other valuable fintech products." “JustiFi has made huge strides since our initial investment in 2021,” said Justin Kaufenberg, Managing Director at Rally Ventures. “They’ve built an unparalleled fintech platform, put together a world-class team of fintech and SaaS+ veterans and onboarded over 40 platform customers who bring more than $10.6 Billion in annual processing volume. We believe JustiFi represents the future of fintech for platforms and we look forward to the journey ahead.” In other recent news, JustiFi announced the release of 11 cutting-edge web components, providing platforms with an even easier and more customizable method to embed fintech products into their existing ecosystems. Additionally, in November of 2023, JustiFi entered into a new partnership with Sezzle, enabling hundreds of platform companies to offer Buy Now, Pay Later (BNPL) services easier than ever before. For more information about the JustiFi platform, please visit www.justifi.tech. About JustiFi: JustiFi, the fintech platform for platforms, enables software companies to monetize white-label fintech products like embedded payments, Buy Now, Pay Later, lending, and insurance faster than ever before. As a registered payment facilitator, JustiFi offers world-class support, assisting our platform partners in achieving 100% customer activation, while guaranteeing seamless fintech experiences for their end users. Contact Details Rachel Subasic rachel@rallyventures.com Company Website https://justifi.tech/

May 22, 2024 08:03 AM Eastern Daylight Time

Video
Article thumbnail News Release

AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and BioConnection, a specialized contract manufacturing organization (CMO) focusing on aseptic filling of vials and syringes for clinical and commercial production, today announced a new strategic partnership. The companies are partnering to provide end-to-end biopharmaceutical development and manufacturing capabilities for drug substance and drug product using the development and manufacturing expertise of AGC Biologics and the specialized aseptic filling capabilities of BioConnection. The new partnership offers a seamless, full-service clinical-stage development and manufacturing solution that accelerates timelines and brings life-saving therapies to market more efficiently. By combining world-class drug substance and drug product services, AGC Biologics together with BioConnection now offer one convenient “gene to vial” value chain service with a single contract and project management team for the project lifecycle. Further, developers will save time and resources by avoiding long, complex processes associated with negotiating a separate drug substance and drug product contract and be able to conveniently plan drug filling activities for as soon as their substance release is scheduled – all through this new offering. New Solution for Companies Potentially Impacted by U.S. BIOSECURE Act This new strategic partnership addresses the ongoing needs of the industry in the wake of the proposed U.S. BIOSECURE Act. By having a combined end-to-end solution that uses facilities in Japan, the United States and Europe, developers now have a reliable and secure supply of services for development, manufacturing (including freeze-drying) and aseptic filling for their drug product’s needs. AGC Biologics is especially well-positioned to support the needs of developers that may be impacted by this legislation, as it is one of the largest CDMO networks in the world offering single-use bioreactor technology. Developers seeking alternatives from their current outsourcing partner benefit from access to AGC Biologics’ single-use network utilizing ubiquitous bioreactor technology, enabling an easier transfer of platform processes and reduction in process changes associated with changing outsourcing partners. Combined Expertise and Resources Through this new joint offering AGC Biologics and BioConnection are providing comprehensive solutions to meet the increasing demand for high-quality biopharmaceutical manufacturing services, while also continuing to offer their services independently. AGC Biologics offers a broad range of protein-biologics services spanning from cell line development to commercial-scale manufacturing across its global network of facilities on three continents, supporting drug substances for microbial and mammalian-based systems, plasmid DNA (pDNA) and messenger RNA (mRNA). With a proven track record of delivering innovative biopharmaceutical solutions to clients worldwide, including supporting more than a dozen commercial products since 2018, AGC Biologics is renowned for its teams with deep technical and scientific expertise at its global facilities, and a commitment to quality, reliability, meeting product timelines and collaborating with developers to meet their needs. BioConnection specializes in aseptic filling of vials and syringes, providing clients with tailored solutions for both clinical and commercial production of either liquid or freeze-dried products. Equipped with state-of-the-art facilities and a highly skilled team, BioConnection is dedicated to ensuring the highest standards of product quality and safety. Clients have valued BioConnection since 2005 for this and for its unmatched customer-oriented approach. “Now more than ever global pharmaceutical companies and developers need reliable facilities to produce and fill their drug products, and by combining our resources with BioConnection we are offering a new end-to-end solution for them under one contract with AGC Biologics,” said Patricio Massera, CEO of AGC Biologics. “We believe BioConnection has a strong acumen, and this partnership will enhance our biopharmaceutical manufacturing offering by providing drug product services for protein biologics, allowing us to create deeper relationships with developers to help get their products to patients in need.” Similarly, Alexander Willemse, CEO of BioConnection, commented, "We are excited to join forces with AGC Biologics to offer integrated manufacturing solutions that address the complexities of biopharmaceutical development. Together, we are well-positioned to support our clients at every stage." For more information about AGC Biologics please visit www.agcbio.com. Visit www.bioconnection.eu to learn more about BioConnection. About BioConnection: BioConnection is a specialized contract manufacturing organization (CMO) focusing on aseptic filling and lyophilization of vials and syringes for clinical and commercial production. With state-of-the-art facilities, a proven successful EMA and FDA track record and a team of experienced professionals in Oss, The Netherlands, BioConnection provides tailored solutions to meet the unique needs of clients in the biopharmaceutical industry. BioConnection is specialized in fill & finish and lyophilization of small and large molecules, orphan drugs, personalized medicine and controlled substances. Its customers value BioConnection for its reliability. BioConnection is renowned for its reliability, with customers appreciating the certainty of delivery made possible by its extensive capacity. The company combines this reliability with a personalized approach to client relations. Discover more at www.bioconnection.eu. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com BioConnection Dennis Link +31 412 846 036 Company Website https://www.agcbio.com/

May 22, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Technology Select Sector SPDR Fund (XLK) Continues to be a Mainstay in Technology Investing

Select Sector SPDR

The Technology Select Sector SPDR Fund ( XLK ), with its comprehensive coverage of U.S. technology, remains a pillar in investment strategies for individuals and institutions alike. With its focus on the components of the S&P 500 in technology industries, XLK offers an efficient way to gain exposure to this dynamic sector. The ETF is carefully structured, featuring a roster of technology giants that have shown resilience. The fund's composition reflects substantial holdings in some of the most influential and innovative companies in the U.S. Key Holdings* of the Technology Select Sector SPDR Fund (XLK) Include: Microsoft Corporation (22.59%) Apple Inc (20.41%) Broadcom Inc (4.72%) Nvidia Corporation (4.58%) Salesforce Inc (2.92%) Advanced Micro Devices Inc (2.87%) Adobe Inc (2.35%) Cisco Systems Inc (2.14%) Accenture (2.12%) Qualcomm Incorporated (2.08%) The XLK ETF's large market position is reflective of the sector's ongoing importance and innovation, with total assets surpassing $62 billion and an expense ratio of 0.09%**. Investors looking for diversified exposure to the tech sector will find XLK's concentrated yet comprehensive portfolio alignment appealing. The Technology Select Sector SPDR Fund allows for participation in the exciting XLK ETF composed of these tech behemoths, while offering diversification across multiple technology industries. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 4/30/24 subject to change **Ordinary brokerage fees apply DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007521 EXP 7/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

May 22, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

SWEP Celebrates 30 Years of Commitment to Promote Environmental Stewardship

Prodigy Press Wire

Forest Health Field Day. The students were planting blister rust-resistant Sugar Pine saplings. Sierra Watershed Education Partnerships (SWEP) celebrates a remarkable 30-year milestone this year, marking three decades of commitment to promoting stewardship by connecting students to sustainability, and environmental conservation. SWEP's journey began in 1994 when a group of parents and teachers founded the organization. Although they officially gained nonprofit status in 1997, the organization's roots were firmly planted in connecting local students to their natural surroundings. Over the years, SWEP has evolved, receiving grants, collaborating with partners, and expanding its reach to promote stewardship and service learning. Missy Mohler, SWEP Executive Director Executive Director Missy Mohler reflects on SWEP's early struggles, highlighting the challenges of obtaining nonprofit status. “Despite these hurdles, SWEP has emerged resilient, and we are dedicated to fostering hope and empowering students to take action for the environment.” Missy Mohler's words resonate as a testament to SWEP's perseverance. A significant focus for SWEP lies in addressing pressing environmental issues, from wildfires to waste management. The organization empowers students by engaging them in hands-on projects, like defensible space initiatives. Through these experiences, students learn the importance of their contributions and gain practical knowledge about environmental challenges. Waste management and sustainability are at the core of SWEP's initiatives. By running sustainability clubs and conducting food waste audits, SWEP actively involves students in solutions to combat issues like plastic pollution and methane emissions. The organization's commitment to waste diversion is evident in its success, having diverted 13,000 pounds of food waste last school year. Environmental conservation takes center stage as SWEP's High School clubs travel to various schools and communities, emphasizing the significance of reusable items and advocating against single-use plastics. Their impact extends beyond education, influencing local policies such as the ban on single-use plastics, and showcasing the tangible outcomes of their efforts. The organization's partnerships with schools in the Tahoe Truckee region underscore its commitment to diversity, recognizing it as a key asset for success. Despite past challenges, SWEP has navigated budget closures and grant freezes, securing support through grants, sponsorships, community partners, and generous donations. SWEP calls for funding to support its mission of connecting students to the environment and contributing to the natural world. Over 10,000 student connections in the past five years speak to the organization's reach. The strategic plan outlines ambitious goals, emphasizing equitable programming, outdoor education, and cultural connections with the Washoe indigenous tribe. SWEP remains steadfast in its belief that exposing students to nature will shape a positive future. By intertwining cultural history and respecting the natural world, SWEP aims to create a meaningful learning environment that fosters environmental consciousness. Media Contact: Name: Simone Tenorio Email: info@4swep.org Release ID: 1029713

May 21, 2024 07:30 PM Eastern Daylight Time

Image
Article thumbnail News Release

Flynn Gold discovers significant high-grade gold at Link Zone

FLYNN GOLD LIMITED

Flynn Gold Ltd (ASX:FG1) CEO Neil Marston joins Proactive’s Jonathan Jackson to discuss the discovery of a new high-grade mineralisation zone at Link Zone prospect within the Golden Ridge Project in Northeast Tasmania. A recent field mapping and sampling campaign at the historic Golden Ridge adit revealed high-grade veins, with underground grab sampling recording assays of 64.4 g/t, 37.6 g/t and 15.9 g/t gold. These findings have driven the company’s share price up by as much as 48.2%, reaching $0.04. The Link Zone prospect is strategically located between the Trafalgar and Brilliant prospects along the Golden Ridge granodiorite contact, hosting a corridor of high-grade gold mineralisation with a potential strike length of 2.5 kilometres and vertical extent of at least 500 metres. Previous diamond drilling at Trafalgar and Brilliant yielded outstanding results, with multiple intersections exceeding 100 g/t of gold at Trafalgar. This is being further investigated through an active diamond drilling campaign. The new mineralised veins at Link Zone present fresh drill targets, potentially extending the existing gold system. Currently, Phase 3 diamond drilling at Trafalgar is in progress, with samples from the first hole under laboratory analysis. The drill program aims to infill test high-grade zones from previous programs and explore extensions to known mineralisation along the gold-bearing granodiorite-metasediment contact, now extending over 9 kilometres. Marston, stated that the Link Zone results enhance their confidence in the extensive, high-grade gold system at Golden Ridge, with ongoing exploration efforts aimed at identifying additional drilling targets. Contact Details Proactive Investors Proactive Australia Pty Ltd +61 431 597 771 writers.australia@proactiveinvestors.com

May 21, 2024 07:20 PM Eastern Daylight Time

Video
Article thumbnail News Release

Prescient Therapeutics PTX-100 shows promising results in Phase 1b study

PRESCIENT THERAPEUTICS LIMITED

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the results of its PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in California from June 6 to 8. The Phase 1b study targeted patients with relapsed and refractory T-cell lymphomas (r/r TCLs) and successfully met its primary objectives of demonstrating safety and determining pharmacokinetics and pharmacodynamics. Additionally, the study showed a promising preliminary efficacy with a 45% overall response rate, where five out of 11 evaluable patients responded positively to the treatment. T-cell lymphomas are a rare type of non-Hodgkin lymphoma, classified as an orphan disease with about 30,000 cases. PTX-100 has received Orphan Drug Designation from the US FDA, highlighting the need for more effective treatments for TCLs, particularly for relapsed and refractory cases. The T-Cell Lymphoma Forum is a specialised conference focused on advancements in TCL treatment, bringing together clinicians, scientists and industry professionals. Yatomi-Clarke, emphasised the importance of this platform for sharing critical research and the significance of PTX-100 in addressing an unmet medical need. The company plans to advance to a Phase 2 trial in r/r TCL, expected to commence in Q3 2024. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

May 21, 2024 06:15 PM Eastern Daylight Time

Video
Article thumbnail News Release

Josip Heit in an Interview with NATIONAL TIMES AUSTRALIA about Wikipedia and the Revolution in News Consumption in the digital age

500NewsWire

Sydney, Australia, May 21, 2024 - ( 500NewsWire ) -- Josip Heit, a name that is gaining increasing prominence in the international business world, has earned a firm place among today's leading businessmen through his innovative approaches and entrepreneurial vision. Known for his ability to successfully realize forward-looking projects, Heit has left an impressive mark in various industries. Against this backdrop, NATIONAL TIMES AUSTRALIA conducted an interview with Josip Heit at a time characterized by rapid technological development and in which online dailies have established themselves as the predominant source of news and information. In this context, as can also be seen on Wikipedia, Heit currently owns 45 daily newspapers with his media group. Heit plans to increase the number to 50 daily newspapers on all continents under the umbrella of his media group by the End of the year. 2024. NATIONAL TIMES AUSTRALIA: Mr Heit, you currently have 45 daily newspapers that publish news from around the world in six languages around the clock, seven days a week. Where do you see the difference to the past compared to printed newspapers? Josip Heit: " Printed newspapers formed the backbone of journalism for decades. Today, we are experiencing a profound shift towards digital news consumption. Traditional forms of media such as print newspapers and television are steadily losing importance, while digital platforms and social media are becoming increasingly influential. Printed newspapers deliver yesterday's news; they are usually printed at night and often only reach the reader the next day when the information is already outdated." NATIONAL TIMES AUSTRALIA: What makes online daily newspapers so successful, and what challenges and opportunities does this present for the industry and readers? Josip Heit: "With the increasing spread of the internet and the availability of smartphones and tablets, people's reading habits have changed drastically. Online daily newspapers offer quick and easy access to the latest news, often in real time. Users can find out about events worldwide around the clock without having to wait for the next edition of the printed newspaper. A key advantage of digital platforms is their multimedia nature. Articles are supplemented by images, videos and interactive graphics, which increase the understanding and depth of reporting. Hyperlinks also allow readers to jump from one article to the next and gather additional information in the process." NATIONAL TIMES AUSTRALIA: You attach great importance to sustainability and have brought legendary daily newspapers back to life. What's that all about? Josip Heit: "While people are still throwing away far too much, I have revitalized centuries-old newspaper titles and secured the trademark rights to them. Examples include "The Peninsula Times" from South Africa: https://en.wikipedia.org/wiki/The_Peninsula_Times or "The HongKong Telegraph" from Hongkong / People's Republic of China: https://en.wikipedia.org/wiki/The_Hongkong_Telegraph as well as "La Gaceta de México" from Mexico: https://en.wikipedia.org/wiki/La_Gaceta_de_M%C3%A9xico and "Bombay Durpun" from India: https://en.wikipedia.org/wiki/The_Bombay_Durpun. Together with our partners, we have also analysed algorithms and the reading behaviour of users in order to suggest tailored content that corresponds to their individual interests. These personalized news streams ensure that readers receive relevant and interesting information without having to search for it. What's more, no reader has to take out a subscription to read news from all over the world, which clearly sets us apart from other media." NATIONAL TIMES AUSTRALIA: Despite the many advantages, online daily newspapers face considerable challenges, especially when it comes to monetization. How do you solve the problem if you don't sell subscriptions? Josip Heit: "While printed newspapers were able to rely on sales revenue and advertising, digital platforms have to find creative ways to generate revenue. Paywalls, subscriptions and digital advertising are common models, but are often met with resistance from users who are used to free content. We solve this problem with advertising. These are placed by our advertising partners, which gives readers free access to news and allows our advertising partners to draw attention to themselves." NATIONAL TIMES AUSTRALIA: Another problem is the spread of fake news and the credibility of sources. In the digital world, anyone can publish information, which makes it difficult for readers to distinguish trustworthy news from fake news. Josip Heit: " Reputable online daily newspapers need to focus more on quality and fact-checking in order to stand out from dubious sources. Technological innovations such as artificial intelligence and augmented reality help here. I support EU Commissioner Thierry Breton in creating a safe and trustworthy digital space, combined with an improved legal framework and relentless pursuit of fake news, falsehoods, and defamation on the internet." NATIONAL TIMES AUSTRALIA: What role does journalism play as a guardian of democracy and informant of the public in the digital world? Josip Heit: "Journalism acts as the fourth estate in the state, alongside the legislative, executive and judicial branches. Its task is to expose abuses of power and corruption and to create transparency. Journalists investigate, research and critically scrutinize the actions of governments, companies, and other powerful institutions. Through their reporting, they ensure that the powerful are held accountable, and that citizens are informed about important political and social developments. In this context, online daily newspapers have revolutionized the way we consume news. Their ability to deliver up-to-date, multimedia and personalized content makes them an indispensable part of modern life. This presents exciting opportunities for the evolution of journalism." NATIONAL TIMES AUSTRALIA: Thank you very much for the Interview. You can read the entire interview at ‘The National Times’ here: https://www.TheNationalTimes.au/Economy/308277-josip-heit-in-an-interview-with-national-times-australia-about-wikipedia-and-the-revolution-in-news-consumption-in-the-digital-age.html Press Contact: THE NATIONAL TIMES AUSTRALIA Florence Taylor Tower/2 Darling Park Levels 20 2000 Sydney NSW Tel.: +61480089450 Fax: +61480089451 E-Mail: Info@TheNationalTimes.au Web: https://www.TheNationalTimes.au Information about "THE NATIONAL TIMES" 53 years ago, (Status as of May 2024), "The National Times", an Australian daily and later weekly newspaper, was first published in 1971 by John Fairfax Limited. "The National Times" rapidly established a reputation for accurate investigative journalism, winning four consecutive Walkley Awards for best newspaper feature in 1975, 1976, 1977 and 1978. Contact Details THE NATIONAL TIMES AUSTRALIA Info@TheNationalTimes.au

May 21, 2024 06:07 PM Eastern Daylight Time

Image
1 ... 151152153154155 ... 3725